Skip to main content

Applying novel, high throughput screening technologies to deliver therapeutics that address the most difficult problems in clinical medicine



Targeting Nuclear Receptors

Nuclear receptors can bind ligand, leading to a conformational change, homo- or hetero-dimerization, nuclear translocation and DNA binding.

Driving Apoptosis of Senolytic Cells

DNA damage, oxidative stress or oncogenic mutations can activate nuclear translocation of p53 and p53 interacting proteins (p53IP), helping to tether p53 onto the transcriptional promoter of pro-senescence protein, p21.

Deliver Graphic


Our early pipeline is focused on identifying novel drug candidates, both small molecules or peptides, that target nuclear receptors, senolytics and tyrosine kinases.



December 14, 2021 in Press Releases

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

DELIVER Therapeutics, Inc. ("DELIVER") a company that plans to apply novel, high-throughput screening technologies combined with chemical innovation to DELIVER therapeutics that address the most difficult problems in clinical medicine has been launched with an initial $3M Convertible…
Read More
November 15, 2021 in News

New use of screening technology finds SARS-CoV-2 treatment target in lab setting

Finding effective treatments for SARS-CoV-2, the viral agent responsible for COVID-19, has been difficult but researchers at Baylor College of Medicine are working to find a potential solution. Much attention…
Read More